Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-31
1997-02-11
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540482, 540604, 544160, 544383, 546309, 546335, 546336, 546337, 548542, 548950, 549 68, 549480, 560 13, 560150, 562427, 562430, 562470, 564 78, 564 79, 514212, 514183, 5142382, 514255, 514329, 514352, 514357, 514424, 514472, 514447, 514539, 514541, 514599, 514600, 514562, C07C30702, A61K 3118, A61K 3140, A61K 31535
Patent
active
056021194
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 PCT/US93/10460 filed Oct. 29, 1993.
BACKGROUND OF THE INVENTION
1. Field of the invention
The present invention relates to retroviral protease inhibitors and, more particularly, relates to novel compounds and a composition and method for inhibiting retroviral proteases. This invention, in particular, relates to sulfamic acid-containing hydroxyethylamine protease inhibitor compounds, a composition and method for inhibiting retroviral proteases such as human immunodeficiency virus (HIV) protease and for treating a retroviral infection, e.g., an HIV infection. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
2. Related Art
During the replication cycle of retroviruses, gag and gag-pol gene products are translated as proteins. These proteins are subsequently processed by a virally encoded protease (or proteinase) to yield vital enzymes and structural proteins of the virus core. Most commonly, the gag precursor proteins are processed into the core proteins and the pol precursor proteins are processed into the viral enzymes, e.g., reverse transcriptase and retroviral protease. It has been shown that correct processing of the precursor proteins by the retroviral protease is necessary for assembly of infectious virons. For example, it has been shown that frameshift mutations in the protease region of the pol gene of HIV prevents processing of the gag precursor protein. It has also been shown through site-directed mutagenesis of an aspartic acid residue in the HIV protease that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.
Retroviral protease inhibition may involve a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral replication proteases can be effectively inhibited.
Several classes of compounds have seen proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such compounds include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, "Rational Design of Peptide-Based Proteinase Inhibitors," Science, 248, 358 (1990); and Erickson et al, "Design Activity, and 2.8 .ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990).
Several classes of compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. Pat. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB 2,209,752. EP O 264,795, U.S. SIR H725 and U.S. Pat. No. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. G.B. 2,200,115 also discloses sulfamic acid-containing hydroxyethylamine renin inhibitors, and EP 0264 795 discloses certain sulfamic acid-containing hydroxyethylamine renin inhibitors. However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is directed to virus inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and to intermediates useful in such processes. The subject compounds are characterized as sulfamic acid-containing hydroxyethylamine inhibitor compounds.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided a retroviral protease inhibiting compou
REFERENCES:
patent: H725 (1990-01-01), Gordon
patent: 4146645 (1979-03-01), Schromm et al.
patent: 4252804 (1981-02-01), Joulli e et al.
patent: 4450164 (1984-05-01), Bristol et al.
patent: 4477441 (1984-10-01), Boger et al.
patent: 4514391 (1985-04-01), Gordon et al.
patent: 4548926 (1985-10-01), Matsueda et al.
patent: 4599198 (1986-07-01), Hoover
patent: 4616088 (1986-10-01), Ryono et al.
patent: 4668769 (1987-05-01), Hoover
patent: 4668770 (1987-05-01), Boger et al.
patent: 4757050 (1988-07-01), Natarajan et al.
patent: 4880938 (1989-11-01), Freidinger
patent: 4908386 (1990-03-01), Finch et al.
patent: 4963530 (1990-10-01), Hemmi et al.
patent: 4977277 (1990-12-01), Rosenberg et al.
Roberts et al, "Rational Design of Peptide-based Proteinase Inhibitors," Science, 248, 358 Apr. (1990).
Erickson et al, "Design Activity, and 2.8.ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 Aug. (1990).
Pearl et al, "Sequence specificity of retroviral proteases" Nature, 328, p. 482 Aug. (1987).
Martin, Drugs of the Future, 16(3), 210-212 (8) (1991).
Meek et al, Letter To Nature, 343, 90-92 Jan. (1990).
McQuade et al, Science, 274, 454-456 Jan. (1990).
Rich et al, Peptide Inhibitors of Proteases, 511-520 Month and Year Not Available.
Rosenberg et al, J. Med. Chem., 30, 1224-1228 (1987). Month not available.
Thornber, C. W.; Chemical Society Reviews, vol. 8, No. 1, @1979, pp. 563-580.
Dickinson, Proc. Annual Meet. Med. Sect. Am. Counc. Life Insurance @1993.
DeCrescenzo Gary A.
Getman Daniel P.
Mueller Richard A.
Sun Eric T.
Talley John J.
Richter Johann
Stockton Laura L.
Ungemach Frank s.
LandOfFree
Succinoylamino hydroxyethylamino sulfamic acid derivatives usefu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Succinoylamino hydroxyethylamino sulfamic acid derivatives usefu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Succinoylamino hydroxyethylamino sulfamic acid derivatives usefu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342194